In vivo evaluation of a novel antitumor prodrug, 1-(2′-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation

International Journal of Radiation Oncology Biology Physics

Volumn 49, Issue 2, 2001, Pages 407-413

  Shibamoto, Yuta ^a,c   Zhou, Ling ^b   Hatta, Hiroshi ^b   Mori, Mayuko ^b   Nishimoto, Sei Ichi ^b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

5 Fluorouracil; Hypoxia; Prodrug; Radiation; Radiation activated

Indexed keywords

FLUOROURACIL; FLUOROURACIL DERIVATIVE; OFU001; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER; CANCER RADIOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HYPOXIA; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMBINED MODALITY THERAPY; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUOROURACIL; MICE; MICE, INBRED C3H; PRODRUGS; RADIOTHERAPY DOSAGE; TUMOR CELLS, CULTURED;

EID: 0035254229     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01490-5     Document Type: Conference Paper

References (24)

1. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
2. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
3. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer
4. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix
5. Oxygenation of head and neck cancer; Changes during radiotherapy and impact on treatment outcome
6. Radiation, hypoxia and genetic stimulation; Implication for future therapies
7. The hypoxic cell; A target for selective cancer therapy-Eighteenth Bruce F. Cain Memorial Award lecture
8. Modification of hypoxia-from Gottwald Schwarz to nicotinamide. Have we learned the lesson?
9. Carcinoma of the cervix and the use of hyperbaric oxygen with radiotherapy; A report of a randomised controlled trial
10. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
11. A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy
12. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole
13. Tirapazamine-cisplatin; The synergy
14. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas; A phase II study
15. Novel radiation sensitizers targeting tissue hypoxia
16. Reduction of nitroarylmethyl quaternary ammonium prodrugs of mechlorethamine by radiation
17. Radiation-activated prodrugs as hypoxia-selective cytotoxins; Model studies with nitroarylmethyl quaternary salts
18. 1-(5′-fluoro-6′-hydroxy-5′, 6′-dihydrouracil-5′-yl)-5-fluorouracil, a novel N(1)-C(5)-linked dimer that releases 5-fluorouracil by radiation activation under hypoxic conditions
19. A novel class of antitumor prodrug, 1-(2′-oxopropyl)-5-fluorouracil (OFU001) that release 5-fluorouracil upon hypoxic irradiation
20. The radiation response of SCCVII tumor cells in C3H/He mice varies with the irradiation conditions
21. Oral vehicle administration before radiation causes radioprotection of murine SCCVII tumors
22. Combined effect of clinically relevant doses of emitefur, a new 5-fluorouracil derivative, and radiation in murine tumours
23. Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer
24. Assessment of micronucleus induction in murine SCCVII cells treated with various anticancer agents